MedPath

Bright Light Therapy in Seasonal Affective Disorder (SAD)

Not Applicable
Conditions
Seasonal Affective Disorder
Interventions
Other: Bright light therapy
Other: Inactive "placebo-light"
Registration Number
NCT01030276
Lead Sponsor
University of Oulu
Brief Summary

The aim of this study is to investigate the efficacy of bright light therapy in SAD. This is a placebo-controlled, double-blind randomized controlled trial (RCT).

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
60
Inclusion Criteria
  • a patient has, according to the DSM-IV-TR, a Major depression, recurrent episode, seasonal pattern, "moderate" or "severe" (classification code 296.32 and 296.33)
  • HAMD-21 (included in the SIGH-SAD) sum score is ≥ 22
  • patient is over 18 years
  • patient can read and understand the subject information sheet
  • patient has signed the informed consent form
  • patient is not pregnant
Exclusion Criteria
  • patient has a lifetime psychotic disorder
  • patient has a DSM-IV Axis I disorder other than some anxiety disorder evaluated by MINI
  • patient has some DSM-IV-TR Axis II disorder, which is likely to interfere with the study treatment according to the investigator
  • patient has alcohol or some other substance use dependence or misuse
  • life-time suicide attempt, or any thought of suicide during the last month
  • patients has some unstable somatic disorder
  • patient uses some medication on regular basis
  • patient uses some herbal psychotropic agencies
  • patient is, in the opinion of the investigator, unsuitable for any reason
  • patient is a member of the site personnel or their immediate families
  • patient has had bright light therapy during the current episode
  • patient has some eye disease (patient can, however, be myopic or hyperopic)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Bright lightBright light therapy-
Inactive "placebo-light"Inactive "placebo-light"-
Primary Outcome Measures
NameTimeMethod
Remission as defined by the SIGH-SAD28 (visit window from 26 to 30 days) days after the inclusion day
Secondary Outcome Measures
NameTimeMethod
Decrease of the severity of symptoms as assessed by SIGH-SAD, Hamilton anxiety scale, and Beck depression inventory-2128 (visit window from 26 to 30 days) days

Trial Locations

Locations (1)

Research unit, ODL Terveys Oy, Albertinkatu 18 A

🇫🇮

Oulu, Finland

© Copyright 2025. All Rights Reserved by MedPath